Compare Abbott Laboratories (ABT) vs Unity Software Inc (U) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Unity Software Inc — how do they compare? Abbott Laboratories trades at $95.43 (market cap $166.94B), while Unity Software Inc trades at $29.36 (market cap $12.95B). The key difference: Abbott Laboratories is far larger — about 12.9× Unity Software Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Unity Software Inc pays none. Which is the better fit depends on your goals.
| ABT | U | |
|---|---|---|
Market Cap | $166.94B | $12.95B |
Sector | Health | Technology |
52-Week High | $136.62 | $49.47 |
52-Week Low | $82.57 | $17.13 |
Enterprise Value | $193.69B | $13.04B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Unity Software (U) trades at $29.66, up 1.16% today, with a bullish technical outlook and strong analyst support. The stock shows improving fundamentals with revenue stable at $1.85 billion in 2025 and narrowing losses, while operating cash flow grew to $423 million. Recent news highlights Unity's strategic pivot toward AI-driven advertising and developer tools, boosting investor confidence despite ongoing net losses.
The outlook is cautiously optimistic with a consensus price target of $36.50 implying 23% upside. Key opportunities include AI integration and margin expansion, but risks persist from competitive pressures, high debt, and profitability challenges. Investors should weigh growth potential against execution risks in the evolving tech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →
